Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
19 hedge funds and large institutions have $2.2M invested in Baudax Bio, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 16 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
21% less capital invested
Capital invested by funds: $2.78M → $2.2M (-$580K)
32% less funds holding
Funds holding: 28 → 19 (-9)
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.13M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.09M |
| 3 |
Renaissance Technologies
New York
|
+$1.08M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$186K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$159K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.02M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$152K |
| 3 |
State Street
Boston,
Massachusetts
|
-$62K |
| 4 |
AWA
Amplius Wealth Advisors
Blue Bell,
Pennsylvania
|
-$54K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$41K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CBB
26
Citizens Business Bank
Ontario,
California
| – | -$5K | -16 | Closed |
|
|
ASN
27
Advisory Services Network
Atlanta,
Georgia
| – | -$3K | -11 | Closed |
|
|
SIP
28
Stoneridge Investment Partners
Radnor,
Pennsylvania
| – | -$3K | -11 | Closed |
|
29
Victory Capital Management
San Antonio,
Texas
| – | -$3K | -9 | Closed |
|
30
Group One Trading
Chicago,
Illinois
| – | -$369 | -2 | -29% |
|
31
Wells Fargo
San Francisco,
California
| – | -$185 | -1 | Closed |
|
|
CA
32
CoreCap Advisors
Southfield,
Michigan
| – | -$1K | – | – |
|
33
JP Morgan Chase
New York
| – | +$738 | +4 | New |
|
BXRX Hedge Fund Activity: Q1 2022 in Review
19 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q1 2022, worth a combined $2.2M — down 21% from $2.78M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of BXRX and 7 opened new positions — a net loss of 9 holders — while 2 trimmed existing stakes and 8 added.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $2.13M. The largest seller was Armistice Capital, exiting entirely with an estimated $1.02M sold.
- 19 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q1 2022, down from 28 in Q4 2021.
- Funds reported $2.2M of Baudax Bio, Inc. Common Stock stock for Q1 2022, down 21% quarter-over-quarter.
- 7 funds opened new Baudax Bio, Inc. Common Stock positions in Q1 2022 and 16 closed out, a net change of -9 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q1 2022 was Alyeska Investment Group, an estimated $2.13M added.
- The largest Baudax Bio, Inc. Common Stock seller in Q1 2022 was Armistice Capital, an estimated $1.02M sold.
Based on aggregated 13F filings for Q1 2022.